Hudson Bay Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5M | Buy |
+15,348
| New | +$5M | 0.02% | 390 |
|
|
2025
Q1 | – | Sell |
-7,500
| Closed | -$1.76M | – | 883 |
|
|
2024
Q4 | $1.76M | Sell |
7,500
-10,762
| -59% | -$2.53M | 0.01% | 514 |
|
|
2024
Q3 | $5.02M | Sell |
18,262
-11,738
| -39% | -$3.23M | 0.02% | 297 |
|
|
2024
Q2 | $7.29M | Sell |
30,000
-92,500
| -76% | -$22.5M | 0.03% | 232 |
|
|
2024
Q1 | $18.3M | Buy |
122,500
+40,000
| +48% | +$5.98M | 0.1% | 81 |
|
|
2023
Q4 | $15.8M | Buy |
82,500
+36,600
| +80% | +$7.01M | 0.1% | 100 |
|
|
2023
Q3 | $8.13M | Buy |
+45,900
| New | +$8.13M | 0.06% | 162 |
|
|
2021
Q1 | – | Sell |
-20,000
| Closed | -$2.6M | – | 839 |
|
|
2020
Q4 | $2.6M | Buy |
+20,000
| New | +$2.6M | 0.03% | 326 |
|
|
2020
Q1 | – | Sell |
-60,000
| Closed | -$6.91M | – | 482 |
|
|
2019
Q4 | $6.91M | Sell |
60,000
-300
| -0.5% | -$34.6K | 0.15% | 124 |
|
|
2019
Q3 | $4.85M | Sell |
60,300
-154,700
| -72% | -$12.4M | 0.13% | 144 |
|
|
2019
Q2 | $15.6M | Buy |
215,000
+165,000
| +330% | +$12M | 0.36% | 45 |
|
|
2019
Q1 | $4.67M | Sell |
50,000
-5,000
| -9% | -$467K | 0.06% | 164 |
|
|
2018
Q4 | $4.01M | Sell |
55,000
-5,000
| -8% | -$365K | 0.05% | 193 |
|
|
2018
Q3 | $5.25M | Buy |
60,000
+30,000
| +100% | +$2.63M | 0.06% | 145 |
|
|
2018
Q2 | $2.96M | Buy |
+30,000
| New | +$2.96M | 0.04% | 229 |
|